About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.


Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. More >

News & Events

Jul 29, 2015 MannKind Announces Stock and Note Exchange Agreements With Holders of Outstanding... More >
Jun 09, 2015 Career of Diabetes and Medical Pioneer Al Mann Honored at Boston Gala More >
May 27, 2015 MannKind to Present at Upcoming Conferences More >